Serum Anti-heat Shock Protein 27 Antibody Titers in Patients With Dyslipidemia: A Population-based Case-control Study

F. Sadabadi, M. Shahi, Sousan Darroudi, Azam Rastgar Moghadam, Sahar Heidari-Bakavoli, Asma Porsa, Sara Saffar Soflaei, H. Esmaeili, M. Mouhebati, Ghodratollah Salehi Sangani, G. Ferns, Bibi Razieh Hoseini Farash, M. Ghayour-Mobarhan
{"title":"Serum Anti-heat Shock Protein 27 Antibody Titers in Patients With Dyslipidemia: A Population-based Case-control Study","authors":"F. Sadabadi, M. Shahi, Sousan Darroudi, Azam Rastgar Moghadam, Sahar Heidari-Bakavoli, Asma Porsa, Sara Saffar Soflaei, H. Esmaeili, M. Mouhebati, Ghodratollah Salehi Sangani, G. Ferns, Bibi Razieh Hoseini Farash, M. Ghayour-Mobarhan","doi":"10.32598/jid.26.1.7","DOIUrl":null,"url":null,"abstract":"Background: Heat shock protein 27 (HSP27) is found in several cell types of adults, such as cardiomyocytes, and endothelial cells. It is expressed in response to different cellular stress conditions. HSP27 decreases the levels of reactive oxygen species (ROS) and dyslipidemia is closely associated with increased endothelial production of reactive oxygen species (ROS). Objective: Higher serum HSP27 antigen and anti-HSP27 antibodies have been reported in patients with unstable angina and myocardial infarction Methods: This population-based case-control study was conducted in 2018. We investigated serum anti-HSP27 antibody titers in all participants with dyslipidemia from the Mashhad stroke and heart atherosclerotic disorder (MASHAD) study (n=8141) and those who were healthy in terms of dyslipidemia (n=1637) using an in-house enzyme-linked immune sorbent assay (ELISA) in individuals with dyslipidemia. Findings: Anti-HSP27 titers were significantly lower in individuals with dyslipidemia compared to people without dyslipidemia (P=0.036). Conclusion: Our results revealed that the anti-HSP27 antibody titer was lower in the participants with dyslipidemia than in the negative group. However, there may be a confounding effect of drug therapy. In a subgroup of dyslipidemic subjects, we observed lower anti-HSP27 antibody titers in patients treated with some drugs (statins or corticosteroids, non-steroidal anti-inflammatory drugs [NSAIDs], or anti-diabetic and anti-hypertensive) compared to subjects untreated with these drugs.","PeriodicalId":91544,"journal":{"name":"Journal of inflammatory bowel diseases & disorders","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of inflammatory bowel diseases & disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/jid.26.1.7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Heat shock protein 27 (HSP27) is found in several cell types of adults, such as cardiomyocytes, and endothelial cells. It is expressed in response to different cellular stress conditions. HSP27 decreases the levels of reactive oxygen species (ROS) and dyslipidemia is closely associated with increased endothelial production of reactive oxygen species (ROS). Objective: Higher serum HSP27 antigen and anti-HSP27 antibodies have been reported in patients with unstable angina and myocardial infarction Methods: This population-based case-control study was conducted in 2018. We investigated serum anti-HSP27 antibody titers in all participants with dyslipidemia from the Mashhad stroke and heart atherosclerotic disorder (MASHAD) study (n=8141) and those who were healthy in terms of dyslipidemia (n=1637) using an in-house enzyme-linked immune sorbent assay (ELISA) in individuals with dyslipidemia. Findings: Anti-HSP27 titers were significantly lower in individuals with dyslipidemia compared to people without dyslipidemia (P=0.036). Conclusion: Our results revealed that the anti-HSP27 antibody titer was lower in the participants with dyslipidemia than in the negative group. However, there may be a confounding effect of drug therapy. In a subgroup of dyslipidemic subjects, we observed lower anti-HSP27 antibody titers in patients treated with some drugs (statins or corticosteroids, non-steroidal anti-inflammatory drugs [NSAIDs], or anti-diabetic and anti-hypertensive) compared to subjects untreated with these drugs.
血脂异常患者血清抗热休克蛋白27抗体滴度:一项基于人群的病例对照研究
背景:热休克蛋白27 (HSP27)存在于多种成人细胞类型中,如心肌细胞和内皮细胞。它在不同的细胞应激条件下表达。HSP27降低活性氧(ROS)水平,血脂异常与内皮细胞活性氧(ROS)生成增加密切相关。目的:有报道称,不稳定型心绞痛和心肌梗死患者血清HSP27抗原和抗HSP27抗体升高。方法:该研究于2018年开展,基于人群的病例对照研究。我们使用内部酶联免疫吸附试验(ELISA)对血脂异常患者的血清抗hsp27抗体滴度进行了研究,研究对象为来自Mashhad卒中和心脏动脉粥样硬化性疾病(MASHAD)研究的所有血脂异常患者(n=8141)和血脂异常健康患者(n=1637)。结果:血脂异常患者的抗hsp27滴度明显低于无血脂异常患者(P=0.036)。结论:血脂异常组抗热休克蛋白27抗体滴度低于阴性组。然而,药物治疗可能会产生混淆效应。在血脂异常受试者亚组中,我们观察到接受某些药物治疗的患者(他汀类药物或皮质类固醇、非甾体抗炎药[NSAIDs]、抗糖尿病和抗高血压药)的抗hsp27抗体滴度较未接受这些药物治疗的患者低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信